This is not an "extreme" speculation. After reviewing all the facts at hand, it is 100-percent reasonable and rational to conclude:
1) The Phase 3 DCVax-L trial failed, or was largely unsuccessful;
2) They are nearing certification on a new manufacturing facility;
3) They are holding off on announcing 1 until 2 is confirmed. That way they can temper the bad news with some good news.
Now, whether the certification of the manufacturing facility ends up benefiting NWBO shareholders remains to be seen. It is possible that it could, yes. But the company hasn't told us anything about how that will work and, more importantly, the Cognate precedent suggests otherwise. It is equally plausible that NWBO is about to become a manufacturing company, or that history will repeat itself i.e., Cognate and once again NWBO shareholders will be left holding the bag. I always go with precedent because once people show you who they are, you'd be a fool to not understand that's who they really are.
Regardless, the above scenario is far from an extreme outcome. It is perfectly reasonable and rational based on the facts we know. I believe this very scenario is about to reveal itself as soon as the manufacturing certification is in hand. The posters here are so obsessively focused on the DCVax-L trial, which is misguided because the company has known for six years that the trial is a bust, and both Dr. Liau and Dr. Ashkan gave up on it a long time ago. I believe NWBO has been 90+ percent focused on manufacturing for some time now.
Why is NWBO refusing to release the data from their Phase 3 trial when they locked the data before Oct. 5, 2020? (Hint: it doesn't have anything to do with COVID.)
